Pharmaceutical Law & Industry Report® Index-Summary

ZENPEP

– Exocrine pancreatic insufficiency drug approved by FDA, 1052

ZETIA

– Cholesterol drug unfavorable trial results, class action settled (D.N.J.), 908
– Overcharging, makers to settle with purchasers (D.N.J.), 1247

ZITHROMAX

– Approval, In Brief, 782

ZOMETA

– Biophosphonates blamed for osteoporosis, summary judgment denied (M.D. Tenn.), 995
– Bone-building drug not withdrawn for safety or effectiveness reasons, FDA says, 448
– Economic and pain and suffering, plaintiff awarded damages (Mont. Dist. Ct.), 1254

ZONEGRAN

– Epilepsy drug may cause metabolic acidosis, FDA report, 236

ZOSYN

– Antibiotic, generic approval challenged (D.D.C.), 1099; TRO deneid, 1130

ZYPREXA

– Adolescents, FDA panel backs use for mental illnesses, 715
– Antipsychotic drug overpayments, class certification for third party payers granted (2nd Cir.), 152
– Causation expert who stretched the truth disqualified (E.D.N.Y.), 587
– Diabetes and death blamed on drug, summary judgment denied (E.D.N.Y.), 1071
– Failure-to-warn suits time-barred (E.D.N.Y.), 768
– Illegal marketing, maker settles with Conn. Atty. Gen. (E.D.N.Y.), 1131
– Off-label uses, Lilly settles with Justice Dep't (E.D. Pa.), 93
– S.C. Atty. Gen. settles fraudulent marketing suit (S.C. Cir. Ct.), 1249
– Suicide blamed on drug, verdict for maker upheld (5th Cir.), 402
– Unresolved questions, summary judgment for maker denied (E.D.N.Y.), 995
– Warnings would not have changed usage, summary judgment for maker (E.D.N.Y.), 677